Sarepta Therapeutics (SRPT) Revenue (2010 - 2026)

Sarepta Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $730.8 million for Q1 2026.

• In Q1 2026, Revenue rose 448.1% year-over-year to $730.8 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 34.67% YoY), while the FY2025 annual figure was $1.9 billion, down 1.98% from the prior year.
• Revenue for Q1 2026 stood at $730.8 million, up from $442.9 million in the prior quarter.
• The five-year high for Revenue was $1.1 billion in Q4 2023, with the low at $133.3 million in Q1 2025.
• The 5-year median for Revenue is $399.4 million (2025), against an average of $446.8 million.
• The sharpest annual moves came in 2022 and 2025: Revenue surged 923.65% in 2022, then tumbled 67.75% in 2025.
• Sarepta Therapeutics' Revenue stood at $866.3 million in 2022, then advanced by 24.46% to $1.1 billion in 2023, then tumbled by 38.93% to $658.4 million in 2024, then plunged by 32.73% to $442.9 million in 2025, then surged by 64.99% to $730.8 million in 2026.
• Business Quant data shows SRPT's Revenue at $730.8 million in Q1 2026, $442.9 million in Q4 2025, and $399.4 million in Q3 2025.